Press Releases

23 Oct, 2023, 07:30 ET CRANBURY, N.J., Oct. 23, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with an institutional investor for […]

28 Sep, 2023, 07:30 ET Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023 Interim Analysis of Initial 120 Patients Showed  Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye  Excellent Patient Safety and Tolerability Product

 22 Sep, 2023, 16:00 ET  CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted

 07 Sep, 2023, 16:00 ET  CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023

 07 Sep, 2023, 07:30 ET  Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrated: Excellent safety and tolerability product profile  Potential for PL9643 to address multiple signs and symptoms of dry eye disease  CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing

 10 Aug, 2023, 07:30 ET  ~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated bremelanotide with a PDE5i Phase 2 clinical study in PDE5i non-responder ED patients currently expected to commence in 4Q 2023  CRANBURY, N.J., Aug.